Elacestrant
123 interactions 283 cited referencesElacestrant is used to treat certain types of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults who have had disease progression following treatment with at least one other hormone therapies. Elacestrant is in a class of medications called estrogen recep… Read the full Elacestrant drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Elacestrant Rifapentine Priftin Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Ritonavir Norvir Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Rosuvastatin Crestor Increased rosuvastatin exposure and an increased risk of rosuvastatin-related adverse effects Details Elacestrant Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Elacestrant Saquinavir Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Sirolimus Felycin Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Elacestrant St John's Wort Reduced elacestrant exposure and reduced efficacy of elacestrant Details Elacestrant Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Elacestrant Tacrolimus Astagraf Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Elacestrant Talazoparib Talzenna Increased talazoparib exposure and an increased risk of talazoparib-related adverse reactions Details Elacestrant Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Elacestrant Telaprevir Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Telithromycin Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Tolvaptan Jynarque Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Elacestrant Topotecan Hycamtin Increased topotecan exposure and risk of adverse events Details Elacestrant Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Elacestrant Ubrogepant Ubrelvy Increased ubrogepant exposure Details Elacestrant Venetoclax Venclexta Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Elacestrant Verapamil Calan Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Voriconazole Vfend Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Ketoconazole Topical Extina® Foam Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Elacestrant Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Elacestrant Letermovir Injection Prevymis Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Elacestrant Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Elacestrant Nafcillin Injection Unipen® Injection Reduced elacestrant exposure and reduced efficacy of elacestrant DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist